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ABSTRACT: Sulfadimethoxine is extensively used in rabbit breeding for preventive and curative purpose and residues 
are sometimes observed in carcasses at slaughter. It has been suggested this is due to dosage and/or duration of 
treatment not being in compliance with the manufacturer’s recommendations, which probably induces residue levels in 
the meat above the maximum residue limit (MRL) value of 100 µg/kg. In order to test this hypothesis, a study was carried 
out on gravid rabbits and their progeny. The animals were subjected to an extended treatment with sulfadimethoxine 
at therapeutic level in the feed. The feed was supplemented before pelleting with a commercial veterinary product 
containing 20 g of trimethoprim and 93 g of sulfadimethoxine per kg. On the basis of the dosage indicated for this 
commercial veterinary product, the incorporation level in the feed was 5 kg/ton (i.e. 465 g of sulfadimethoxine/ton), 
providing oral daily therapeutic treatment of the animals of ca. 12.5 to 50 mg of sulfadimethoxine per kg bodyweight. 
The mothers were treated during the last 21 d of pregnancy and during the whole period of lactation (35 d). The animals 
were sacrifi ced after a wash-out period of 12 d with blank feed. The young rabbits received the supplemented feed after 
weaning during the fi rst 40 d of the fattening period. These animals were also sacrifi ced after a wash-out period of 8, 12, 
15 or 20 d, respectively, with a blank feed. A sample of the leg muscle was taken for analysis. An HPLC analytical method 
was used to determine the sulfadimethoxine concentrations in tissue, with a LLOQ (Lower Limit Of Quantifi cation) of 
50 µg/kg of muscle (trimethoprim was not considered in this study). Sulfadimethoxine concentrations above the MRL 
value of 100 µg/kg were registered only in muscle from 1 out of 8 mothers and in 2 out of 8 young rabbits sacrifi ced 12 d 
after cessation of the treatment. For other young rabbits sacrifi ced on the 8th, 15th or 20th d after cessation of treatment, 
Sulphonamide concentrations in muscle always remained below the MRL value (8 animals per slaughtering time). 
These results show that oral treatment of rabbits with veterinary products containing sulfadimethoxine administered 
for a long period at the daily therapeutic level of 12.5 to 50 mg/kg does not seem to induce the accumulation of this 
molecule in muscle.
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INTRODUCTION
Sulfadimethoxine is a long-acting sulphonamide of interest for the prevention and treatment of various 
rabbit diseases, including coccidiosis and colibacillosis, which cause serious problems in commercial 
rabbit breeding. The anti-coccidial activity of sulfadimethoxine has a positive effect on animal mortality, 
carcass weight and feed utilisation. 
Sulfadimethoxine is an amphoteric molecule with high liposolubility. Its intestinal absorption is very 
rapid and its high rate of binding to plasma proteins (more than 90%) is responsible for its long-acting 
properties. The unbound fraction is widely distributed in tissues, secretions and fl uids like milk, bile, 
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amniotic liquid (Wohler et al., 1961). Sulfadimethoxine is metabolised in the liver and eliminated in the 
urine.
Preventive and curative activity of sulfadimethoxine has been demonstrated in rabbit coccidiosis with 
pathogen agents like Eimeria stiedai, E. exigua, E. intestinalis, E. irresidua, E. magna, E. media, E. 
perforans or E. piriformis (Dürr and Lämmler, 1970; Gòmez-Bautista and Rojo-Vázquez, 1986). The 
preventive and curative activity of sulfadimethoxine (in presence of trimethoprim) is generally claimed 
for a daily oral dose of 25 to 50 mg/kg body weight during 5-10 d. This oral dosage corresponds to a 
sulfadimethoxine supplementation of about 450 g/ton of feed.
Sulphonamides are widely used in farm animal nutrition as a veterinary drug for prophylactic and 
therapeutic purposes and their residues in edible tissues are an important concern due to the possibility of 
risk to human health, such as the development of resistance and toxicity (Kim and Lee, 2003; Niessen, 
1998). The effects of Sulphonamides for human health concern the thyroid gland (inhibition of the iodine 
metabolism and subsequent thyroid hyperplasia), haematology (rare phenomena of agranulocytosis and 
aplasic anaemia) and hypersensitivity (OMS, 1989). From the chemical point of view, hypersensitivity 
reactions are induced by the sulfamyl group of the Sulphonamide molecules (Davis, 1984). 
For these reasons, both EU as well as US regulations have set a maximum residue limit (MRL) of 100 
µg/kg for Sulphonamides in edible tissues and organs from treated animals (AFSSA/ANMV-French 
Agency for Veterinary Medicinal Products). With the exception of certain veterinary medicinal products, 
a withdrawal time of 12 d after the end of oral treatment is usually proposed for sulfadimethoxine and 
more generally for any product containing a Sulphonamide administered by the oral route.
However, field experience shows that Sulphonamide residues are sometimes detected in rabbit carcasses 
following controls at slaughter. This observation may be correlated to the fact that, according to their 
low toxicity and the extremely rare adverse reactions observed in rabbits, the oral utilisation of these 
molecules as preventive agents is sometimes in the form of addition to drinking water or feed during 
prolonged periods.
The aim of this work was to study the possible influence of prolonged oral treatment with sulfadimethoxine 
at a therapeutic dosage level on the elimination of residues by the treated rabbits. Sulphonamide was 
thus given orally to mother rabbits during pregnancy and the suckling period and also to the young 
rabbits during the post-weaning period. The veterinary medicinal product was used in the feed under 
field conditions, at the dosage recommended by the manufacturer and different withdrawal periods after 
cessation of treatment were considered. 
MATERIALS AND METHODS
Experimental phase
A total of 20 primiparous female Hycole rabbits were used for the experiment, with body weight from 3.5 
to 4.3 kg. Animals were housed in individual cages during the whole period of the study, with free access 
to feed and water.
After a period of acclimatization, the animals were artificially inseminated and pregnant status was verified 
by palpation 11 d later. After dropping (32 d after insemination), 4 mothers and their progeny were not 
treated and were used as controls for the study. Of the 16 remaining animals, only 6 young rabbits were 
maintained with each mother to ensure litter viability. The young remained with their mother during the 
whole lactation period of 5 weeks (date of weaning). Eight mothers were randomly sacrificed 12 d after 
weaning. The 6 young rabbits from the same litter were kept in the same cage during a fattening period of 
48, 52, 55 or 60 d, at each of which times 8 animals were randomly sacrificed. 
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During the study all the animals were fed with two complete pelleted feeds: one was a maternity feed 
given to the mothers during pregnancy and lactation, the other was a fattening feed given to the young 
during the fattening period and also to the mothers during the period between weaning and sacrifice 12 
d later.
Maternity and fattening feeds were given to animals either as blank feed or as feed supplemented with 
an authorized commercial veterinary medicinal product containing sulfadimethoxine (93 g/kg) and 
trimethoprim (20 g/kg ). 
The veterinary medicinal product was incorporated in the feed before pelleting at the supplementation 
level of 5 kg/ton, which meant that sulfadimethoxine was present in the feed at a level of 465 g/ton. At this 
supplementation level and according to the field conditions of use, the daily dosage of sulfadimethoxine 
was about 12.5 to 50 mg/kg bodyweight, which is the normal dosage proposed for preventive and curative 
rabbit treatments. The withdrawal time proposed for edible rabbit tissues under these conditions for 
a treatment duration of 5-10 d is 12 d from the end of treatment. Table 1 presents the different feed 
treatments carried out during the study on the mothers and young.
Sacrifice of rabbits was performed by CO2 narcosis followed by exsanguination by cardiac puncture. 
Muscle was taken from the rear leg and minced with a homogenizer. This location was chosen for 
questions of ease of sampling, repeatability between animals and quantities large enough for the analysis. 
Aliquots of minced tissues were frozen and kept below −75°C until analysis. 
Analytical phase
The analytical method used for the quantification of sulfadimethoxine in the rabbit muscle was developed 
in our laboratory using information from numerous publications concerning the analysis of Sulphonamides 
in biological matrices. 
Standard and reagents
Methanol and chloroform (Sigma-Aldrich, Saint Quentin Fallavier, France) and acetonitrile (VWR, 
Fontenay sous Bois, France) were HPLC grade. Sodium hydroxide, phosphoric acid and n-hexane 
(Riedel-de Haën, Saint Quentin Fallavier, France) were reagent grade. The sulfadimethoxine basis active 
ingredient used for the assays had a purity of 99.4%. The sulfadimethoxine stock standard solution at 
1000 µg/mL was prepared by dissolving in a mixture of methanol, water and sodium hydroxide 1 M 
(125/250/1 v/v/v). The working solutions of sulfadimethoxine (2.5 to 37.5 µg/mL) were obtained by 
dilution in ultrapure water. These solutions remained stable during the whole analysis period. 
Sample preparation
Sulfadimethoxine (but not trimethoprim) was determined in the muscle samples. Five grams of minced 
rabbit muscle were homogenised with a mixture of acetonitrile/water and centrifuged (10 min, 3000 rpm). 
Period of the study Nature of feed
Acclimatization period (10 d) and first 11 d of the pregnancy period 
(mothers)
Maternity/blank
Late part of the pregnancy period (21 d) and whole period of lactation 
(35 d) (mothers and, to a lesser extent, young rabbits)
Maternity/supplemented
From weaning up to 12 d post-weaning (12 d) (mothers) Fattening/blank 
From weaning up to 40 d post-weaning (40 d) (young rabbits) Fattening/supplemented
From 40 d after weaning to sacrifice (young rabbits) Fattening/blank
Table 1: Summary of treatments according to the different steps of the study.
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N-hexane was added to the supernatant, vortex-mixed and centrifuged (5 min, 1000 rpm). Chloroform 
was added to the aqueous layer, vortex-mixed and centrifuged (5 min, 1000 rpm). The organic phase was 
evaporated to dryness at approximately 40°C and reconstituted with the mobile phase for HPLC analysis. 
Each analytical run was accompanied with a daily calibration curve prepared with blank rabbit muscle 
fortified with the working solutions of sulfadimethoxine.
Quality controls (QC) were prepared with blank rabbit muscle spiked with sulfadimethoxine stock 
standards in order to obtain 100 or 600 µg/kg tissue concentration of Sulphonamide. 
These preparations were extracted and analysed during the same analytical runs as for the experimental 
specimens, in order to validate the obtained results.
Parameter Assay conditions Results
Specificity Comparison of chromatograms Presence of a peak on chromatograms resulting 
from the analysis of muscle specimens spiked 
with sulfadimethoxine and absence of this peak 
for the blank specimens
Linearity Range of the tested concentrations: 
50 to 750 µg/kg rabbit muscle
Calibration curve: 
Concentration = Peak area/300901
R2 = 0.998031
Precision Tested concentrations:
50 and 600 µg/kg rabbit muscle 
(6 preparations of each)
%RSD: 4.3 and 5.4%2 
(for 50 and 600 µg/kg, respectively)
Accuracy Tested concentrations: 
50 and 600 µg/kg rabbit muscle 
(6 preparations of each)
Mean error with the theoretical concentration: 
14.0 and 8.0% 
(for 50 and 600 µg/kg, respectively)
Lower limit of 
detection 
(= LLOD)
Estimation from the baseline noise 
after analysis of blank rabbit muscle 
(6 different preparations)
LLOD = 30 µg/kg rabbit muscle
Lower limit of 
quantification 
(= LLOQ)
Lowest concentration tested for 
linearity
LLOQ = 50 µg/kg rabbit muscle
Upper limit of 
quantification 
(= ULOQ)
Highest concentration tested for 
linearity
ULOQ = 750 µg/kg rabbit muscle
Stability of the 
preparations
Tested concentrations: 
50 and 600 µg/kg rabbit muscle 
(3 preparations of each)
1/ Before analysis, the reconstituted preparation 
remained stable at room temperature for 24 h.
2/ Spiked preparations stored at a temperature 
below −75°C remained stable for 66 d before 
extraction and analysis.
Table 2: Main results obtained during the control step of the analytical method.
1 R2 = determination coefficient. 2 RSD: residual standard deviation.
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HPLC analysis
The analysis was performed according to our own method with Waters HPLC materials (Milford, MA, 
USA): 515 pump, 717+ autosampler, 2487 detector and Empower 1 integration system. Separation was 
carried out with a Kromasil C18 column (4.6 mm × 250 mm; 5 µm) (Macherey-Nagel, Düren, Germany) 
protected by a guard column µBondapak C18 (Waters, Milford, MA, USA). The mobile phase was a 
mixture of acetonitrile and 0.02 M phosphoric acid solution (50/50 v/v). The flow rate was 1 mL/min and 
the injection volume was 20 µL. Wavelength for detection was 272 nm. Analysis was performed at room 
temperature.
The analytical method used for the sulfadimethoxine determination in the rabbit muscle was carried out 
without the addition of an Internal Standard in the samples before extraction and was not completely 
validated according to the regulatory specifications in force for the residues of veterinary medicinal 
products in foodstuffs of animal origin. However, different criteria were studied in order to verify that 
this method was well adapted to the expected scope of the study. According to the results obtained (see 
Table 2), it should be emphasized that the analytical method used for the study allows the quantification 
of sulfadimethoxine in rabbit muscle at concentrations above the LLOQ of 50 µg/kg, which is half of the 
MRL related to this tissue. The analytical method presented good precision and accuracy in the tested 
interval of linearity (between 50 and 750 µg/kg muscle). The Sulphonamide remained stable for 66 d in 
spiked muscle homogenates kept below −75°C until analysis; similarly, the muscle extracts were stable at 
room temperature for 24 h before analysis.
RESULTS AND DISCUSSION
The pelleted feeds were analyzed with and without the veterinary medicinal product. Blank feed did 
not contain sulfadimethoxine and the results on supplemented feed confirmed their conformity with the 
theoretical rate of supplementation: 477 and 485 g of sulfadimethoxine per ton of feed for maternity and 
fattening feeds, respectively (theoretical rate of supplementation for a therapeutic effect: 465 g/ton). 
The mothers continuously received the maternity feed spiked with sulfadimethoxine at this therapeutic 
level for 56 d, comprising 21 d of gestation and 35 d lactation. The young rabbits continuously received 
the fattening feed spiked with sulfadimethoxine at this therapeutic level for the first 40 d of the post-
weaning period. Since Sulphonamides transfer through the placental barrier and are also present in the 
milk of the treated mother (Von Fust et al., 1960; Paget et al., 1964), foetuses were likely indirectly in 
contact with the Sulphonamide during the 21 d of the gestation period and young rabbits during the whole 
lactation period (35 d). Moreover, during the lactation period, the young rabbits certainly consumed a 
certain part of the supplemented maternity feed freely accessible in the cage. Finally, it can be considered 
that the young rabbits remained in contact with sulfadimethoxine for a very long period, which can be 
estimated at 96 d: the 21 last d of the gestation period (placental transfer), 35 d of lactation (milk transfer 
and supplemented feed of the mother) and the first 40 d of post-weaning (for this period, at the therapeutic 
daily dosage of 12.5 to 50 mg/kg bodyweight). 
As indicated in Table 1, after the end of treatment with the supplemented feed, the mothers were fed blank 
feed for 12 d before slaughter. The young rabbits were also fed blank feed for 8, 12, 15 or 20 d before 
sacrifice. At each slaughtering time, 8 young rabbits were randomly chosen from among the 16 litters. 
The determination of sulfadimethoxine in rabbit muscle after extraction and HPLC analysis were carried 
out with reference to a daily calibration curve (range 50 to 750 µg/kg). The Sulphonamide concentrations 
in QC presented variations between −30 and +10% with the theoretical concentration values.
Table 3 presents the results of sulfadimethoxine concentration in muscle according to the treatment 
applied and slaughtering time.
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Among the mothers, only 1 out of the 8 animals presented a Sulphonamide concentration in muscle above 
the MRL value of 100 µg/kg.
In the young rabbits, the results of Table 3 lead to the 2 following observations:
1) At the time of first slaughtering (8 d), all the 8 analyzed muscle samples showed 
sulfadimethoxine concentrations below the MRL value, despite the length of treatment at 
therapeutic level. This observation, confirmed by the results obtained on the 15th and 20th d, 
underlines the considerable ability of rabbits to eliminate Sulphonamide residues.
2) The results observed for slaughter at 12 d show variations: of the 8 young rabbits, 2 animals 
presented Sulphonamide concentrations above the MRL value.
The rabbit is an animal species which seems to present a high capacity to eliminate sulfadimethoxine from 
its organism and numerous considerations on the metabolism of Sulphonamides have been reported (Porter, 
1964; Bridges et al., 1968; Adamson et al., 1970). Biotransformation occurs mainly in the liver, where 
the Sulphonamides are subjected to acetylation, glucuronidation and oxidation. The biotransformation of 
such molecules is affected by enzymatic systems (N-acetyltransferases, cytochromes P450, glutathione-
transferases, epoxide hydrolases), whose activity is governed by genetic factors.
Of the metabolic pathways of hepatic transformation, acetylation is the most important degradation 
mode in the rabbit (Adamson et al., 1970; Bridges et al., 1968; Porter, 1964). In this species, the speed 
of the Sulphonamide acetylation varies individually, with genetic control. There are thus fast and slow 
phenotype animals for the acetylation pathways of Sulphonamides (Bridges et al., 1968; Inamura et al., 
1990; Porter, 1964; Song et al., 1999; WHO, 2004).
Sulphonamides are also subjected to glucuronidation in the liver cells. This form of metabolism is present 
to a minor extent in the rabbit species: only sulfadimethoxine-N4 glucuronide is detected in the urine of 
treated animals (not the sulfadimethoxine-N1 glucuronide), and the quantified levels observed in urine are 
very low (0.4-0.8% of the oral dose during a period of 24 h) (Abou-El-Makarem et al., 1967; Adamson 
et al., 1970; Bridges et al., 1968).
Animals and number






Therapeutic concentration in feed for 56 d 
(21 d of gestation + 35 d of lactation)
8 mothers Blank feed for 12 d < MRL for 7 animals 
410 µg/kg for 1 animal
Therapeutic concentration in feed for 40 d 
(beginning at the weaning date)
8 young rabbits Blank feed for 8 d < MRL for 8 animals
8 young rabbits Blank feed for 12 d < MRL for 6 animals
130 and 460 µg/kg 
for 2 animals
8 young rabbits Blank feed for 15 d < MRL for 8 animals
8 young rabbits Blank feed for 20 d < MRL for 8 animals
Table 3: Sulfadimethoxine concentration in muscle of mothers and young rabbits following therapeutic 
treatment in feed and wash-out periods of different lengths.
1 MRL: maximum residue limit.
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As in many other animal species, oxidation of Sulphonamides also occurs in the liver cells of the rabbit. 
The transformations are mediated by the cytochrome P450 family (Roujeau, 2003; Trepanier, 2004; Vyas 
et al., 2006; WHO, 2004). As for the acetyltransferases, it has been reported that cytochromes P450 are 
enzyme systems with genetic polymorphism; for this reason, the concept of slow and fast metabolizers is 
also claimed for this biotransformation pathway (WHO, 2004). Thus, individual variations in the speed of 
the hepatic rate of oxidative reactions are foreseeable for Sulphonamides.
The considerations on the hepatic biotransformation of sulfadimethoxine, with slow and fast metabolizers, 
partly explain the individual variations of the degradation rate which can be expected in the rabbit. In 
the case of an animal with a genetically induced slow acetylation and/or oxidation (slow metabolizer), 
sulfadimethoxine residues will be present during longer periods than in a fast metabolizer. 
A total of 96 young rabbits were used for the study, of which 8 were randomly chosen for the first 
slaughtering time 8 d after cessation of treatment. According to the absence of Sulphonamide residues in 
muscle, these 8 animals could have been fast sulfadimethoxine metabolizers. On another hand, among 
the 8 animals randomly chosen for slaughter from the 88 remaining at 12 d after cessation of treatment, 2 
presented residues in muscle above the MRL value and could therefore be considered as slow metabolizers. 
The same observation may be made for the 8 mothers sacrificed on the 12th d after cessation of treatment 
and chosen from the 16 animals remaining: one of these animals presented sulfadimethoxine residues 
in muscle at a concentration above the MRL value (410 µg/kg) and could thus be considered a slow 
metabolizer. 
Complementary information on sulfadimethoxine residue depletion should be obtained on tissue 
concentrations measured in animals sacrificed sooner after cessation of treatment and/or in liver and 
kidney, the organs involved in the elimination of Sulphonamides. The results obtained in these organs 
could possibly confirm the presence or absence of residues in muscle and thus follow the same pattern of 
residue depletion. 
The Sulphonamide concentrations observed in muscle demonstrate that a period of treatment much longer 
than the proposed therapeutic duration (about 10 times the usual duration of a therapeutic treatment) 
with a feed containing a therapeutic dosage of sulfadimethoxine does not induce accumulation of 
Sulphonamide in the organism of young and adult rabbits. The presence of sulfadimethoxine residues 
in muscle at a concentration level above the MRL value of 100 µg/kg sometimes observed at slaughter 
at 12 d, both for mothers and their young, could perhaps be explained by the concept of fast and slow 
genetic metabolizers. This could also explain the presence of Sulphonamide residues sometimes observed 
in carcasses at slaughter for rabbits treated under field conditions. It should also be remembered that 
field conditions do not always follow the manufacturers’ recommendations, particularly concerning the 
duration of treatment. A minimum wash-out period of 15 d before slaughter would be more appropriate 
for such animals. 
CONCLUSIONS
These results show that the very long period of oral treatment at a therapeutic level under field conditions 
did not induce an accumulation of sulfadimethoxine residues in the muscle of the treated animals. The 
results observed on the 12th d of slaughter could be explained by possible individual genetic differences 
in the hepatic biotransformation of Sulphonamides. Additional studies are necessary to confirm this 
hypothesis. A wash-out period of 15 d or more could be proposed for rabbits receiving orally veterinary 
medicinal products containing sulfadimethoxine during a treatment at therapeutic level under field 
conditions, i.e longer than 5-10 d. At the present time, Sulphonamide is no longer detected in muscle at 
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concentrations above the MRL value and the individual considerations on metabolism are simply matters 
of topical interest.
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